Second Genome Stock
Second Genome offers a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases.
Sign up today and learn more about Second Genome Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Second Genome Stock
Second Genome, a venture-backed Bay Area based life sciences company, is committed to improving the quality of human health through microbiome-based personalized medicine. Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders. Working with academic and commercial collaborators, Second Genome is developing novel diagnostic tools and therapies for unmet needs in gastrointestinal disorders. The company has established a pipeline of microbiome modulators that impact infection, inflammation, and metabolic diseases. Second Genome entered into the first ever big pharmaceutical partnership focused on microbiome drug discovery with Janssen Biotech, Inc. in June 2013 for new treatments for ulcerative colitis.
Chief Scientific Officer
Co-Founder & SVP, Platform Technologies
Janet A. Warrington
Senior Director, Corporate Development
SVP Corporate Development
CEO & President
Co-Founder & Head of Bioinformatics
Sr VP Research & Development
Peter S. DiStefano